InterMune to chop 60 workers in wake of FDA's rejection

Faced with a recent FDA demand for a new trial of its lung drug pirfenidone, InterMune has brought out the budget axe. The Brisbane, CA-based developer (ITMN) says it is cutting 40 percent of its workforce, or 60 people.

It's a far cry from InterMune's preliminary plans to double or perhaps even triple its workforce if it won an approval. Now InterMune is projecting that the cuts can save the developer $12 million a year after taking a special charge of $2.4 million in the second quarter.  

InterMune hit the primary endpoint in only one of two late-stage trials. But with no approved therapies available for idiopathic pulmonary fibrosis--a lethal disease characterized by inflammation and scarring of the lungs--and a positive recommendation from an influential panel of agency experts, the news still came as a surprise to many of the analysts who had projected blockbuster sales figures.

On the day of the rejection, InterMune's shares plunged more than 80 percent.

- here's the story from Bloomberg

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.